Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PKLR | P30613 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792634 | 0.88 | TRPV1 (0.54) | POLBGRM5GRM1GPR119OPRD1 | |
| SCHEMBL3249336 | 0.88 | POLB (0.52) | POLBPKLRGRM5GPR119OPRD1 | |
| SCHEMBL5467346 | 0.86 | PKLR (0.52) | POLBPKLRGRM5GRM1GPR119 | |
| SCHEMBL3436213 | 0.86 | POLB (0.50) | POLBGRM5GPR119OPRD1OPRK1 | |
| SCHEMBL4013541 | 0.86 | POLB (0.56) | POLBPKLRGPR119OPRD1OPRK1 | |
| SCHEMBL2899666 | 0.84 | POLB (0.47) | POLBGRM5GRM1GPR119OPRD1 | |
| SCHEMBL2950039 | 0.84 | POLB (0.47) | POLBGRM5GRM1GPR119OPRD1 | |
| SCHEMBL12701930 | 0.84 | POLB (0.48) | POLBGRM5GPR119OPRD1OPRK1 | |
| SCHEMBL22980531 | 0.82 | POLB (0.49) | POLBGRM5GRM1GPR119OPRD1 | |
| SCHEMBL22980260 | 0.82 | POLB (0.43) | POLBGRM5GRM1GPR119OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010091409-A1 | CERTAIN NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | POLB 1134/4885PKLR 4248/4885GRM5 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.